Authors

• Özlem Türeci (ORCID: https://orcid.org/0000-0002-0623-1497)
• Annaliesa S. Anderson (ORCID: https://orcid.org/0000-0002-6413-1718)
• Kayvon Modjarrad (ORCID: https://orcid.org/0000-0002-6514-5572)
• Juleen Gayed (ORCID: https://orcid.org/0009-0004-2974-5302)
• Xuping Xie (ORCID: https://orcid.org/0000-0003-0918-016X)
• Nicholas Kitchin (ORCID: https://orcid.org/0000-0002-1808-3380)
• Vishva Bangad
• Yanping Hu (ORCID: https://orcid.org/0009-0006-8820-7437)
• Kenneth Koury
• Xia Xu (ORCID: https://orcid.org/0000-0003-3799-0872)
• Kena A. Swanson (ORCID: https://orcid.org/0000-0002-3389-8414)
• Todd Belanger (ORCID: https://orcid.org/0000-0002-3399-9979)
• Mark Cutler (ORCID: https://orcid.org/0000-0002-5302-5477)
• Oyeniyi Diya
• Federico Mensa (ORCID: https://orcid.org/0000-0002-9421-1268)
• Alejandra Gurtman (ORCID: https://orcid.org/0000-0003-3469-1201)
• Uğur Şahin (ORCID: https://orcid.org/0000-0003-0363-1564)
• Hua Ma (ORCID: https://orcid.org/0000-0002-2403-1376)
• Francine S. Lowry
• Jing Zou (ORCID: https://orcid.org/0000-0002-8098-7284)
• David Cooper (ORCID: https://orcid.org/0000-0002-4595-3943)

Institutions

• Pfizer (United States) (US)
• Pfizer (United Kingdom) (GB)
• BioNTech (Germany) (DE)
• The University of Texas Medical Branch at Galveston (US)

Publication Details

Journal

Vaccine

Published

2025-02-24

DOI

https://doi.org/10.1016/j.vaccine.2025.126869

Citations

6

Primary Topic

SARS-CoV-2 and COVID-19 Research

Type

article

Field-Weighted Citation Impact

8.38